The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies

Samankaltaisia teoksia

• Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer
  Tekijä: Al B Benson, et al.
  Julkaistu: (2020-05-01)
• Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease
  Tekijä: Vasantharaja Raguraman, et al.
  Julkaistu: (2026-06-01)
• Aplastic anemia triggered by the Bruton tyrosine kinase inhibitor acalabrutinib in two patients with mantle cell lymphoma – A case report
  Tekijä: Anna Nikkarinen, et al.
  Julkaistu: (2024-08-01)
• Bruton's Tyrosine Kinase (BTK) and Vav1 contribute to Dectin1-dependent phagocytosis of Candida albicans in macrophages.
  Tekijä: Karin Strijbis, et al.
  Julkaistu: (2013-01-01)
• The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies
  Tekijä: Josée Golay, et al.
  Julkaistu: (2017-10-01)